MedPage Today July 8, 2024
— However, vaccine was associated with modest risk of maternal hypertensive disorders
Administration of the maternal respiratory syncytial virus prefusion F (RSVpreF) vaccine (Abrysvo) didn’t come with an increased risk of preterm birth or other negative neonatal outcomes, according to a retrospective study.
Preterm birth, before 37 weeks’ gestation, was actually numerically less common for women who received Pfizer’s maternal RSV vaccine than without it (5.9% vs 6.7%, adjusted OR 0.87, 95% CI 0.62-1.20), Moeun Son, MD, of Weill Cornell Medical College in New York City, and colleagues reported in JAMA Network Open.
No significant differences emerged by vaccination status in small-for-gestational-age birthweight, stillbirth, neonatal ICU admissions, respiratory distress with NICU admissions, or neonatal jaundice, hypoglycemia, or sepsis. Percentages of...
Today's Sponsors
Today's Sponsor